Polycystic Ovarian Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease.
The Polycystic ovarian syndrome pipeline market research report provides a comprehensive overview on the therapeutics under development for Polycystic ovary syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic ovary syndrome and features dormant and discontinued projects.
Key Targets in the Polycystic Ovary Syndrome Pipeline Drugs Market
In the Polycystic ovary syndrome pipeline drugs market the key targets are Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Androgen Receptor, Corticotropin Releasing Factor Receptor 1, Estrogen Receptor, Follicle Stimulating Hormone Receptor, Nuclear Factor Erythroid 2 Related Factor 2, Patatin Like Phospholipase Domain Containing Protein 2 , and Peroxisome Proliferator Activated Receptor Alpha.
PCOS Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Polycystic Ovary Syndrome Pipeline Drugs Market
Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator has the highest number of pipeline products followed by Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Corticotropin Releasing Factor Receptor 1 Antagonist, Estrogen Receptor Agonist, Follicle Stimulating Hormone Receptor Agonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Patatin Like Phospholipase Domain Containing Protein 2 Activator , and Peroxisome Proliferator Activated Receptor Alpha Agonist.
Polycystic Ovary Syndrome Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Polycystic Ovary Syndrome Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the PCOS pipeline drugs market are Oral, Topical, Subcutaneous, and Vaginal. Oral has the maximum number of pipeline products.
Polycystic Ovary Syndrome Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Polycystic Ovary Syndrome Pipeline Drugs Market
The key molecule types in the PCOS pipeline drugs market are Small Molecule, Recombinant Protein, and Cell Therapy.
Polycystic Ovary Syndrome Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Polycystic Ovary Syndrome Pipeline Drugs Market
The major companies in the Polycystic ovary syndrome pipeline drugs market are EffRx Pharmaceuticals SA, AbbVie Inc, Amaro Therapeutics Inc, Annji Pharmaceutical Co Ltd, Arkay Therapeutics LLC, Bayer AG, Besins Healthcare SA, BioRestorative Therapies Inc, Exeltis Pharmaceuticals Holding SL, Jiangsu Hengrui Medicine Co Ltd, Livzon Pharmaceutical Group Co Ltd, Spruce Biosciences Inc, and Zydus Lifesciences Ltd.
Polycystic Ovary Syndrome Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Polycystic Ovary Syndrome Pipeline Drugs Market Overview
Key Targets | Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Androgen Receptor, Corticotropin Releasing Factor Receptor 1, Estrogen Receptor, Follicle Stimulating Hormone Receptor, Nuclear Factor Erythroid 2 Related Factor 2, Patatin Like Phospholipase Domain Containing Protein 2, and Peroxisome Proliferator Activated Receptor Alpha |
Key Mechanisms of action | Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Androgen Receptor, Corticotropin Releasing Factor Receptor 1 Antagonist, Estrogen Receptor Agonist, Follicle Stimulating Hormone Receptor Agonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Patatin Like Phospholipase Domain Containing Protein 2 Activator , and Peroxisome Proliferator Activated Receptor Alpha Agonist |
Key Routes of Administration | Oral, Topical, Subcutaneous, and Vaginal |
Key Molecule Types | Small Molecule, Recombinant Protein, and Cell Therapy |
Major Companies | EffRx Pharmaceuticals SA, AbbVie Inc, Amaro Therapeutics Inc, Annji Pharmaceutical Co Ltd, Arkay Therapeutics LLC, Bayer AG, Besins Healthcare SA, BioRestorative Therapies Inc, Exeltis Pharmaceuticals Holding SL, Jiangsu Hengrui Medicine Co Ltd, Livzon Pharmaceutical Group Co Ltd, Spruce Biosciences Inc, and Zydus Lifesciences Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic ovary syndrome
- The pipeline guide reviews pipeline therapeutics for Polycystic ovary syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polycystic ovary syndrome therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polycystic ovary syndrome therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Polycystic ovary syndrome
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycystic ovary syndrome
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycystic ovary syndrome pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Amaro Therapeutics Inc
Annji Pharmaceutical Co Ltd
Arkay Therapeutics LLC
Bayer AG
Besins Healthcare SA
BioRestorative Therapies Inc
EffRx Pharmaceuticals SA
Exeltis Pharmaceuticals Holding SL
Jiangsu Hengrui Medicine Co Ltd
Livzon Pharmaceutical Group Co Ltd
Spruce Biosciences Inc
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Polycystic ovary syndrome pipeline drugs market?
In the Polycystic ovary syndrome pipeline drugs market the key targets are Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Androgen Receptor, Corticotropin Releasing Factor Receptor 1, Estrogen Receptor, Follicle Stimulating Hormone Receptor, Nuclear Factor Erythroid 2 Related Factor 2, Patatin Like Phospholipase Domain Containing Protein 2 , and Peroxisome Proliferator Activated Receptor Alpha.
-
What are the key mechanisms of action in the Polycystic ovary syndrome pipeline drugs market?
In the Polycystic ovary syndrome pipeline drugs market the key mechanisms of action are Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Androgen Receptor, Corticotropin Releasing Factor Receptor 1 Antagonist, Estrogen Receptor Agonist, Follicle Stimulating Hormone Receptor Agonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Patatin Like Phospholipase Domain Containing Protein 2 Activator , and Peroxisome Proliferator Activated Receptor Alpha Agonist.
-
What are the key routes of administration in the Polycystic ovary syndrome pipeline drugs market?
The key routes of administration in the Polycystic ovary syndrome pipeline drugs market are Oral, Topical, Subcutaneous, and Vaginal.
-
What are the key molecule types in the Polycystic ovary syndrome pipeline drugs market?
The key molecule types in the Polycystic ovary syndrome pipeline drugs market are Small Molecule, Recombinant Protein, and Cell Therapy.
-
What are the major companies in the Polycystic ovary syndrome pipeline drugs market?
In the Polycystic ovary syndrome pipeline drugs market the major companies are EffRx Pharmaceuticals SA, AbbVie Inc, Amaro Therapeutics Inc, Annji Pharmaceutical Co Ltd, Arkay Therapeutics LLC, Bayer AG, Besins Healthcare SA, BioRestorative Therapies Inc, Exeltis Pharmaceuticals Holding SL, Jiangsu Hengrui Medicine Co Ltd, Livzon Pharmaceutical Group Co Ltd, Spruce Biosciences Inc, and Zydus Lifesciences Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.